A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis. Issue 1 (19th November 2018)

• Record Type: Journal Article
• Authors: Latimer, Caitlin S.; Shively, Carol A.; Keene, C. Dirk; Jorgensen, Matthew J.; Andrews, Rachel N.; Register, Thomas C.; Montine, Thomas J.; Wilson, Angela M.; Neth, Bryan J.; Mintz, Akiva; Maldjian, Joseph A.; Whitlow, Christopher T.; Kaplan, Jay R.; Craft, Suzanne
• Is Part Of: Alzheimer's & dementia. Volume 15:Issue 1(2019)
• Page Start: 93
• Page End: 105
• Publication Date: 2018-11-19
• Subjects: Alzheimer's disease -- Nonhuman primate -- Amyloid -- Tau -- Cerebrospinal fluid (CSF) -- Model; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2018.06.3057
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Nonhuman primates may serve as excellent models of sporadic age‐associated brain β‐amyloid deposition and Alzheimer's disease pathologic changes. We examined whether a vervet nonhuman primate model recapitulated pathologic, physiologic, and behavioral features of early Alzheimer's disease. Methods: Nine middle‐aged (mean = 11.2 years) and nine aged (mean = 21.7 years) female vervet/African green monkeys underwent cerebrospinal fluid collection, gait speed measurement, and neuroimaging before neuropathologic assessment. Results: β‐amyloid plaques were identified in all aged vervets and paired helical filament tau immunoreactivity was observed in all animals. Cerebrospinal fluid β‐amyloid42 and gait speed correlated negatively with age and plaque density. Greater plaque and paired helical filament tau burden predicted reduced volumes and CMRg in several brain regions. Discussion: We observed a coordinated set of relationships among neuropathologic, cerebrospinal fluid, imaging, and behavioral modalities consistent with early Alzheimer's disease. Our results support future use of the vervet model to explore disease mechanisms, biomarkers, and novel therapeutic strategies.